Nuvation Bio: HC Wainwright Reiterates Buy, PT Raised to $10

Nuvation Bio: HC Wainwright Reiterates Buy, PT Raised to $10

Nuvation Bio Inc. (NYSE:NUVB) continues to attract investor interest with the financial research firm HC Wainwright reiterating its buy recommendation and raising the price target to $10. This decision comes on the heels of Nuvation Bio's recent FDA approval for its ROS1 inhibitor, taletrectinib, under the brand name IBTROZI, for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC).

The approval of IBTROZI marks a significant milestone for Nuvation Bio, transitioning the company from a clinical-stage biotech entity to a commercial-stage player. Taletrectinib, an oral, potent, CNS-active, selective ROS1 inhibitor, has shown promising results in clinical trials, with a median progression-free survival period of 46 months and a high response rate of 88.8% Japan approves Nuvation Bio's Ibtrozi for advanced ROS1-positive non-small cell lung cancer^[1].

HC Wainwright's analyst team highlights the potential of IBTROZI in the ROS1-positive NSCLC market, estimating a total addressable market (TAM) of approximately $1 billion in the first year of commercial rollout, with roughly 3000 new patients per year in the United States. The firm also notes that taletrectinib's competitive advantages, such as superior durability of response and comparable tolerability, position it favorably against existing therapies like crizotinib, entrectinib, and repotrectinib Nuvation Bio: A Rare Gem In The Risky Biotech Space^[2].

Early rollout data for IBTROZI has been encouraging, with 70 patients starting treatment between June 12, 2025, and July 31, 2025, translating to approximately $148 million in revenue for the first year. This performance exceeds the first-year revenue of Augtyro, a competing drug, which was less than $40 million in 2024 Nuvation Bio: A Rare Gem In The Risky Biotech Space^[2].

The analyst team at HC Wainwright underscores the potential for continued growth, particularly given the high unmet need in the treatment of ROS1-positive NSCLC. The firm estimates that up to 64% of patients eligible for precision oncology treatments have not yet received a targeted therapy, indicating a substantial market opportunity Nuvation Bio: A Rare Gem In The Risky Biotech Space^[2].

With the National Comprehensive Cancer Network (NCCN) updating its NSCLC guidelines to include taletrectinib as a preferred agent for the treatment of advanced ROS1-positive NSCLC, Nuvation Bio is poised to strengthen its market position relative to competitors Japan approves Nuvation Bio's Ibtrozi for advanced ROS1-positive non-small cell lung cancer^[1].

In conclusion, Nuvation Bio's recent FDA approval and the subsequent positive market response have bolstered investor confidence. HC Wainwright's buy recommendation and raised price target reflect the potential for significant growth and profitability, positioning NUVB as an attractive investment opportunity in the biotech space.

References
Japan approves Nuvation Bio's Ibtrozi for advanced ROS1-positive non-small cell lung cancer^[1] https://www.marketscreener.com/news/japan-approves-nuvation-bio-s-ibtrozi-for-advanced-ros1-positive-non-small-cell-lung-cancer-ce7d58dedb8df125
Nuvation Bio: A Rare Gem In The Risky Biotech Space^[2] https://seekingalpha.com/article/4823009-nuvation-bio-rare-gem-risky-biotech-space